Please login to the form below

Not currently logged in
Email:
Password:

Bispecific antibodies

This page shows the latest Bispecific antibodies news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca to present new oncology data at AACR

AstraZeneca to present new oncology data at AACR

The company will be introducing its next wave of IO therapies, sharing the first clinical results for MEDI5752 – a novel bispecific antibody, which simultaneously targets immune checkpoint proteins  in solid tumours. ... Bispecific antibodies are a

Latest news

More from news
Approximately 5 fully matching, plus 23 partially matching documents found.

Latest Intelligence

  • European biotech: a new generation of leaders emerges European biotech: a new generation of leaders emerges

    It hopes to break into the big league with the launch of its own proprietary product by 2025 in addition to a string of collaborations based on its novel antibodies. ... In addition to traditional antibodies, the pipeline also includes antibody drug

  • Deal Watch December 2016 Deal Watch December 2016

    511. BioInvent (Sweden). Pfizer (US). Research collaboration. Development of immuno-regulatory antibodies targeting tumour-associated myeloid cells. ... Technology. Merus. Incyte. $3, 000m. $120m plus $80m equity. Bispecific antibodies.

  • Deal Watch September 2016 Deal Watch September 2016

    In return, Zymeworks is licensing immuno-oncology antibodies from Daiichi Sankyo, in exchange for royalties on sales. ... 624. EngMab / Celgene. Acquisition corporate. T cell bispecific antibodies that bind simultaneously to a tumour antigen and the T

  • Deal Watch June 2016 Deal Watch June 2016

    2 T-cell engaging XmAb bispecific antibodies: XmAb14045 for AML and XmAb13676 for B-cell malignancies (preclinical) and other rights. ... licence. 125. EpimAb Biotherapeutics/ Innovent Biologics. Fabs-In-Tandem immunoglobulin platform to develop multiple

  • Deal Watch April 2016 Deal Watch April 2016

    The collaboration provides GSK with a platform technology to develop bispecific antibodies. ... 125 . Enumeral (US). Pieris (DE). License &option to further programme. Discovery state 388D4 programme of PD1 Monoclonal Antibodies immunotherapies.

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest appointments

  • F-star hires ex-BMS immuno-oncology leader

    Dr Kayitalire’s background will be of benefit to F-star, as it looks to advance its bispecific antibody pipeline in oncology. ... pipeline. As we saw at the recent ASCO meeting, bispecific antibodies are leading a paradigm shift in cancer care and the

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....